These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38248566)

  • 1. Chronic Hepatitis C Cascade of Care in Prisoners-Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy.
    Cambianica A; Marchese V; Pennati F; Faustinelli A; Migliorati M; Roda F; Spinetti A; Zaltron S; Fiorentini S; Caruso A; Quiros-Roldan E; Castelli F; Focà E
    Int J Environ Res Public Health; 2024 Jan; 21(1):. PubMed ID: 38248566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
    Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
    Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
    Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
    Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program.
    Masarone M; Caruso R; Aglitti A; Izzo C; De Matteis G; Attianese MR; Pagano AM; Persico M
    Dig Liver Dis; 2020 May; 52(5):541-546. PubMed ID: 32234417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C treatment outcome among people in prison: The SToP-C study.
    Ryan H; Dore GJ; Grebely J; Byrne M; Cunningham EB; Martinello M; Lloyd AR; Hajarizadeh B
    Liver Int; 2024 Nov; 44(11):2996-3007. PubMed ID: 39192724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
    Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
    Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
    J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life experience of hepatitis C treatment in a Spanish prison.
    Tejera-Pérez RJ; Iglesias-Gómez A; Oliva-Oliva A; Rodríguez-Alonso B; Alonso-Sardón M; Sánchez Ledesma M; Carbonell-Muñoz C; Pendones Ulerio J; Muñoz-Bellido JL; Belhassen-García M
    Rev Esp Quimioter; 2022 Jun; 35(3):273-278. PubMed ID: 35441836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating hepatitis C cascade of care surveillance system in Tuscany, Italy, through a population retrospective data-linkage study, 2015-2021.
    Ceccarelli L; Moretti G; Mazzilli S; Petri D; Corazza I; Rizzo C; Lucenteforte E; Vainieri M; Seghieri C; Tavoschi L;
    BMC Infect Dis; 2024 Mar; 24(1):362. PubMed ID: 38553731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV micro-elimination in two prisons in Milan, Italy: A model of care.
    Giuliani R; Casigliani V; Fornili M; Sebastiani T; Freo E; Arzilli G; Scardina G; Baglietto L; Tavoschi L; Ranieri R
    J Viral Hepat; 2020 Dec; 27(12):1444-1454. PubMed ID: 32815623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
    Rance J; Lafferty L; Treloar C;
    Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solving the Gap Between HCV Detection and Treatment in Prison HCVRNA Testing and Treatment in a Cohort of Newly Arrived Convicts in Southern Italy.
    Izzo C; Masarone M; Torre P; Melara G; De Matteis G; De Luna A; Pagano AM; Persico M
    Rev Recent Clin Trials; 2021; 16(4):396-402. PubMed ID: 34126911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Virus Elimination Program among Prison Inmates, Israel.
    Eisen L; Mor Z; Madar M; Rabinovitch R; Dadon Y; Sheffer R; Kaliner E; Goldstein L
    Emerg Infect Dis; 2023 Nov; 29(11):2358-2361. PubMed ID: 37877627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.